Hasil Pencarian - Liliana Devizzi

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

    IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma oleh Maria Cristina Pirosa, Marianna Sassone, Barbara Kiesewetter, Armando Lopez Guillermo, Liliana Devizzi, Eva Domingo Domènech, Alessandra Tucci, Donato Mannina, Michele Merli, Antonio Salar, Carlo Visco, Fabiana Esposito, Luisella Bonomini, Emanuele Zucca, Andrés J. M. Ferreri, Markus Raderer

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells

    Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells oleh Filippo de Braud, Francesca De Santis, Roberta Zappasodi, Massimo Di Nicola, Margherita Ambrosini, Michele Magni, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Serenella M Pupa, Liliana Devizzi, Paola Matteucci, Antonello Cabras, Andrea Anichini, Alessandro M Gianni

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyResearch in context

    Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyResearch in context oleh Marek Trněný, Abraham Avigdor, Matthew S. McKinney, Shankara Paneesha, Björn E. Wahlin, John S. Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

    Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome oleh Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, Francesca Ricci, Giuseppe Rossi, Carmelo Carlo-Stella, Paolo Corradini

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

    Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomiz... oleh Riccardo Bruna, Fabio Benedetti, Carola Boccomini, Caterina Patti, Anna Maria Barbui, Alessandro Pulsoni, Maurizio Musso, Anna Marina Liberati, Guido Gini, Claudia Castellino, Fausto Rossini, Fabio Ciceri, Delia Rota-Scalabrini, Caterina Stelitano, Francesco Di Raimondo, Alessandra Tucci, Liliana Devizzi, Valerio Zoli, Francesco Zallio, Franco Narni, Alessandra Dondi, Guido Parvis, Gianpietro Semenzato, Francesco Lanza, Tommasina Perrone, Francesco Angrilli, Atto Billio, Angela Gueli, Barbara Mantoan, Alessandro Rambaldi, Alessandro Massimo Gianni, Paolo Corradini, Roberto Passera, Marco Ladetto, Corrado Tarella

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

    IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma oleh Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Hervé Ghesquières, Gerardo Musuraca, Francesca Gaia Rossi, Francesco Merli, Romain Guièze, Emmanuel Gyan, Guido Gini, Dario Marino, Remy Gressin, Franck Morschhauser, Federica Cavallo, Francesca Palombi, Annarita Conconi, Benoît Tessoulin, Hervé Tilly, Manuela Zanni, Maria Giuseppina Cabras, Enrico Capochiani, Catello Califano, Melania Celli, Alessandro Pulsoni, Francesco Angrilli, Ubaldo Occhini, René-Olivier Casasnovas, Guillaume Cartron, Liliana Devizzi, Corinne Haioun, Anna Marina Liberati, Roch Houot, Michele Merli, Giuseppe Pietrantuono, Francesca Re, Michele Spina, Francesco Landi, Franco Cavalli, Francesco Bertoni, Davide Rossi, Nicoletta Ielmini, Elena Borgo, Stefano Luminari, Emanuele Zucca, Catherine Thieblemont

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: